Company will gain access to a considerable pipeline of liquid products covering various disease areas
Company will gain access to a considerable pipeline of liquid products covering various disease areas
DEVOTE grant will allow acute care patient access and a supporting infrastructure for the company
EO2463 is an experimental treatment for indolent non-Hodgkin B cell lymphoma
Researchers show silver retains antimicrobial activity for longer when it is infused into bioactive glass
Find out more about the PharmaTimes Communications Awards 2023 – key dates, categories and which charity we have partnered with this year!
Preliminary data has shown excellent safety, while also demonstrating proof of mechanism
Gilead will present real-world data on its efforts to advance WHO’s aim of eliminating viral hepatitis
525-patient trial intends to assess ‘complement activation’ during HD in patients with end stage renal failure
VLA1553 had a high seroresponse rate among participants 28 days after receiving a single administration
The treatment candidate, known as MDI-26478, is a positive allosteric modulator of the AMPA receptor
Objective response rate and complete response rates were encouraging for both treatments
International data questions the assumption that chronic myeloid leukaemia is now a ‘solved’ disease
Erdafitinib boosted survival in patients with certain conditions including metastatic urothelial carcinoma
Emergence of quick test follows recent dramatic increase in sexually transmitted infections
Laboratory space will accelerate the development of potentially life-saving cell therapies